Observational analysis shows selenium significantly reduces tumor volume in Wistar rats, indicating chemopreventive potential.
Background: Breast cancer remains a significant global public health concern, necessitating the ongoing exploration of novel preventive and therapeutic strategies. Selenium supplementation has been proposed as a potential chemopreventive agent, yet its efficacy lacks robust in vivo validation. Aims: This study aimed to evaluate the chemopreventive potential of selenium supplementation and its effect on tumor progression in a 7,12-dimethylbenz[a]anthracene (DMBA)-induced breast cancer model in Wistar rats. Methods: Twenty-four adult female Wister rat were allocated into four experimental groups (n=6): Control (vehicle only); DMBA (carcinogen control); DMBA + Se 200 µg/kg; and DMBA + Se 400 µg/kg. Mammary tumors were induced via a single intragastric administration of DMBA (80 mg/kg). Over a 23-week period, hematological, biochemical, and histopathological analyses were conducted. The volume of excised mammary tumors was measured post-sacrifice. Results: Supplementation with selenium at a dose of 400 µg/kg resulted in a statistically significant reduction in mean tumor volume (0.13 cm³) compared to the DMBA-only group (1.32 cm³). Concurrently, this high-dose group exhibited significant amelioration in serum levels of specific biochemical markers including aspartate aminotransferase (AST), urea, and creatinine. Histopathological assessment further supported these findings, revealing a more preserved mammary tissue architecture in rats receiving the high-dose selenium. Conclusions: While selenium supplementation at 400 µg/Kg demonstrated a significant inhibition effect on tumor progression and conferred hepatorenal protection, a definitive chemopreventive effect against DMBA-induced carcinogenesis was not established. These results indicate that selenium may function as a therapeutic modulator rather than a primary preventive agent in this model. Further investigation employing higher doses and alternative administration regimens is warranted to elucidate its full chemopreventive potential.
No takes yet. Share an insight, caveat, or question.
Djebara et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: